Effect of Flaxseed as a Treatment for Adults With Type 2 Diabetes Mellitus in Mexico

NCT ID: NCT06683235

Last Updated: 2024-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-30

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Type 2 Diabetes Mellitus represents one of the most important health emergencies of this century Although it is known that insulin resistance is reversible and that type 2 diabetes mellitus is controllable with a change towards a healthy lifestyle, the population ignores these recommendations and continues with their unhealthy habits. Thus, the number of patients continues to grow exponentially, which leads to an increase in economic expenditure on health. This is why non-pharmacological measures are sought that favor the reduction of glycemia in patients with Diabetes Mellitus where the consumption of functional foods is a good alternative for the treatment of this chronic disease. Flaxseed is a food characterized by its nutritional properties, highlighting its content of alpha linoleic acid, flax lignans, and secoisolariciresinol diglucosides. The latter have antioxidant, lipid-lowering and hypoglycemic effects, which makes it an excellent option as a functional treatment for type 2 diabetes.

The aim of this study is to assess the adjuvant effects of flaxseed consumption (14 gr of flaxseed) on biochemical markers (glucose, glycosylated hemoglobin, total cholesterol, triglycerides, LDL cholesterol and HDL cholesterol) in adult patients (30 to 70 years) with type 2 diabetes mellitus in Oaxaca.

Procedures Patients who sign the informed consent will be assigned a group according to the following: if they have an even number in their file, they will be part of the control group (A), and if they have an odd number, they will be part of the intervention group B.

Group A. They will be given a verbal instruction to continue with the treatment established by the treating physician, and they will be given nutritional guidance with the help of the healthy eating plate.

Group B. They will be given verbal instructions to continue with the treatment established by the treating physician, they will be given nutritional guidance with the help of the healthy eating plate and they will be given a leaflet with written instructions and photos on how to consume flaxseed and its benefits.

The researchers will purchase, package and provide the flaxseed powder to the members of group B. The flaxseed will be delivered in packages with 16 gr of ground flaxseed each, which will be given to the patients for daily consumption.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Researchers Dra. Sabina López Toledo (Responsible) Maria Cruz Pineda De la Cruz General objective To assess the adjuvant effects of flaxseed consumption (14 gr of flaxseed) on biochemical markers (glucose, glycosylated hemoglobin, total cholesterol, triglycerides, LDL cholesterol and HDL cholesterol) in adult patients (30 to 70 years) with type 2 diabetes mellitus, who attend the Nutrition outpatient clinic of the Regional Hospital in Oaxaca.

Specific objectives

1. To describe the sociodemographic variables (age, sex, occupation, marital status) of adult patients (30 to 70 years) with type 2 diabetes, who attend the Nutrition outpatient clinic of the Regional Hospital in Oaxaca.
2. Describe the clinical characteristics (time of disease evolution, type of treatment, control and comorbidities) of adult patients (30 to 70 years) with type 2 diabetes who attend the Nutrition outpatient clinic of the Regional Hospital in Oaxaca.
3. Assess the biochemical parameters (glucose, glycosylated hemoglobin, total cholesterol, triglycerides, LDL cholesterol and HDL cholesterol) of adult patients (30 to 70 years) with type 2 diabetes who attend the Nutrition outpatient clinic of the Regional Hospital in Oaxaca, prior to consuming flaxseed and three months after regular consumption of flaxseed.
4. Apply a nutritional intervention to two groups: Group A) Teaching about the healthy eating plate and Group B) Teaching about the healthy eating plate and indicating the consumption of flaxseed.
5. To evaluate the effect of flaxseed consumption on biochemical markers (glucose, glycosylated hemoglobin, total cholesterol, triglycerides, LDL cholesterol and HDL cholesterol of adult patients (30 to 70 years) suffering from type 2 diabetes, who attend the Nutrition outpatient clinic of the Regional Hospital in Oaxaca.
6. To analyze the most effective possible combinations (pharmacological + non-pharmacological) for the treatment of adult patients (30 to 70 years) suffering from type 2 diabetes, who attend the Nutrition outpatient clinic of the Regional Hospital in Oaxaca.

Justification Type 2 Diabetes Mellitus represents one of the most important health emergencies of this century. It is estimated that in 2019 there were already 463 million people with diabetes mellitus worldwide and that this figure may increase to 578 million by 2030 and 700 million by 2030. million by 2045. A state of hyperglycemia is associated with acute and chronic complications, in both cases affecting the cardiovascular system, mainly the blood vessels and consequently the entire body, but mainly the eyes, kidneys, arteriovenous systems and peripheral nerves. Although it is known that insulin resistance is reversible and that type 2 diabetes mellitus is controllable with a change towards a healthy lifestyle, the population ignores these recommendations and continues with their unhealthy habits. Thus, the number of patients continues to grow exponentially, which leads to an increase in economic expenditure on health. This is why non-pharmacological measures are sought that favor the reduction of glycemia in patients with Diabetes Mellitus where the consumption of functional foods is a good alternative for the treatment of this chronic disease. Flaxseed is a food characterized by its nutritional properties, highlighting its content of alpha linoleic acid, flax lignans, and secoisolariciresinol diglucosides. The latter have antioxidant, lipid-lowering and hypoglycemic effects, which makes it an excellent option as a functional treatment for type 2 diabetes.

Description of the procedures Patients who sign the informed consent will be assigned a group according to the following: if they have an even number in their file, they will be part of the control group (A), and if they have an odd number, they will be part of the intervention group B.

Group A. They will be given a verbal instruction to continue with the treatment established by the treating physician, and they will be given nutritional guidance with the help of the healthy eating plate.

Group B. They will be given verbal instructions to continue with the treatment established by the treating physician, they will be given nutritional guidance with the help of the healthy eating plate and they will be given a leaflet with written instructions and photos on how to consume flaxseed and its benefits.

Phase 3. Flaxseed administration The researchers will purchase, package and provide the flaxseed powder to the members of group B. The flaxseed will be delivered in packages with 16 gr of ground flaxseed each, which will be given to the patients for daily consumption (one 8 gr spoonful of flaxseed in the morning snack and one 10 gr spoonful of flaxseed in the morning snack).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

DIABETES Mellitus Type 2 Not Well Controlled

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention with flaxseed

Participants in the intervention group will be given 16 g of ground flaxseed per day for 3 months.

Group Type EXPERIMENTAL

flaxseed

Intervention Type DIETARY_SUPPLEMENT

Participants in the intervention group will be given 16 g of ground flaxseed per day for 3 months.

Control group

control group, without intervention.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

flaxseed

Participants in the intervention group will be given 16 g of ground flaxseed per day for 3 months.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Oaxaca individuals between 30 and 70 years old.
* patients who attended the Nutrition outpatient clinic at the Oaxaca Hospital President "Benito Juárez" diagnosed at most one year ago and who agreed to participate in the study by signing the informed consent.
* Patients with a diagnosis of uncontrolled type 2 diabetes, evidenced by biochemical markers, with a maximum validity of 1 month (fasting blood glucose greater than 140 and glycosylated hemoglobin greater than 6.5%).
* Patients with regular attendance at the outpatient clinic, for at least 3 consecutive months.

Exclusion Criteria

* Patients diagnosed with chronic kidney disease on renal function replacement therapy.
* Patients with glucose disorders secondary to autoimmune diabetes, thyroid diseases or insulin-producing tumors.
* Patients with a medical history of poor drug adherence.
* Patients with adequate glycemic control evidenced by clinical laboratory tests for at least 2 months.
* Patients who do not have a means of contact for follow-up.
* Patients who are pregnant and have gestational diabetes.
Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad Autónoma Benito Juárez de Oaxaca

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sabina López Toledo

Professor Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sabina Lopez Toledo, Doctorate

Role: PRINCIPAL_INVESTIGATOR

Universidad Autónoma Benito Juárez de Oaxaca (UABJO)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Regional Presidente Juárez

Oaxaca City, Oaxaca, Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CEI-04/2023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Acute Metabolic Effects of Melatonin Treatment
NCT03204877 COMPLETED PHASE1/PHASE2